Abstract
Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have